



Curriculum Vitae

Personal information **Suzana Vidic**

Work experience

1. Employer: Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (JAZMP)
 - Start date: October 2018
 - End date: present
 - Position: nonclinical and clinical assessor
 - Activities: nonclinical and clinical assessments: marketing authorisation procedures for human medicinal products (CP, DCP/MRP, NP), clinical trials, different regulatory activities in the field of biologicals, including ATMPs
 - Country: Slovenia
2. Employer: Institute of biochemistry, Faculty of Medicine, University of Ljubljana
 - Start date: May 2017
 - End date: September 2018
 - Position: Senior researcher
 - Activities: Experimental biochemistry and basic research of cancer: _ targeted genomics (e.g. qRT_PCR) _ cell based functional assays (estrogen biosynthesis and metabolism, transport assay) _ HPLC with radioisotope detection Clinical trial _ protocol design
 - Country: Slovenia
3. Employer: University of Primorska, FAMNIT, Koper
 - Start date: October 2015
 - End date: September 2016
 - Position: Assistant and researcher
 - Activities: _ Teaching courses: Psychopharmacology, Molecular basis of neurodegeneration, Research methodology. _ Research project: clinical study on KASP genotyping
 - Country: Slovenia
4. Employer: Janssen Pharmaceuticals Beers & Erasmus Medical Centre, Rotterdam (The Netherlands)
 - Start date: May 2012
 - End date: August 2014
 - Position: Postdoctoral researcher
 - Activities: Development and characterization of better predictive tumour models for drug discovery: _ cell cultures (2D/3D mono and co_cultures) _ tumor growth kinetic (e.g. spectrofluorometer, confocal microscopy) _ drug screening _ immunological methods (immunocytochemistry, immunohistochemistry) _ in vivo animal studies
 - Country: The Netherlands, Belgium
5. Employer: InteRNA b.v., Utrecht
 - Start date: December 2010
 - End date: November 2011
 - Position: Postdoctoral researcher
 - Activities: Identification and validation of anti-angiogenic miRNA-based therapeutics: _ detection and amplification of miRNA (stem_loop qRT_PCR) _ cell based functional screening (e.g. cell proliferation, tube formation assay)
 - Country: The Netherlands
6. Employer: Department of Experimental Oncology, Institute of Oncology Ljubljana
 - Start date: October 2004
 - End date: April 2009
 - Position: Research fellow
 - Activities: Gene therapy of cancer: _ molecular cloning (e.g. vector design and cloning) _ DNA transfer methodologies (cell transfection, lentiviral transduction) _ cell based functional assays (e.g. apoptosis, proliferation) _ molecular biology (e.g. Western blot, RT_PCR) _ immunological methods (fluorescence microscopy, ELISA, Western blot, flow cytometry) _ non_clinical testing of gene_based therapeutics in animal models of cancer (anti_tumor activity) _ in situ genomic analysis (FFPE)
 - Country: Slovenia
7. Employer: Department of Biotechnology, National institute of Chemistry Ljubljana
 - Start date: October 2003
 - End date: September 2004
 - Position: Research technician
 - Activities: Experimental biochemistry : _ HPLC analysis _ monitoring of enzyme's kinetic parameters and post_translational modifications
 - Country: Slovenia

Education and training

1. Subject: Accreditation in carrying out and supervising the conduct of animal experiments. Erasmus Medical Centre, Rotterdam
 - Start date: December 2012
 - End date: January 2013
 - Qualification: FELASA C certificate
 - Organisation: Erasmus Medical Centre, Rotterdam
 - Country: The Netherlands
2. Subject: Biomedical Science
 - Start date: October 2004
 - End date: March 2009

- Qualification: PhD degree in Biomedical sciences
 - Organisation: Faculty of Medicine Ljubljana, University of Ljubljana
 - Country: Slovenia
3. Subject: Molecular Biology
- Start date: October 1997
 - End date: July 2003
 - Qualification: MSc degree in Biology
 - Organisation: Biotechnical faculty, University of Ljubljana
 - Country: Slovenia

Additional information

Publications

Pavlič R, Vidic S, Anko M, Knific T, Büdefeld T, Marton K, Sinreich M, Poschner S, Jäger W, Frković_Grazio S, Rižner TL. Altered Profile of E1_S Transporters in Endometrial Cancer: Lower Protein Levels of ABCG2 and OSTβ and Up_Regulation of SLCO1B3 Expression. *Int J Mol Sci.*2021;22(8):3819.doi: 10.3390/ijms22083819.

Vidic S, Estrada MF, Gjerde K, Santo VE, Osswald A, Barbier M, Chong YT, Sommergruber W, de Hoogt R, Brito C, Graeser R. PREDECT Protocols for Complex 2D/3D Cultures. *Methods Mol Biol.* 2019; 1888:1_20. doi: 10.1007/978_1_4939_8891_4_1.

Roviš D, Černelič Bizjak M, Vasiljev Marchesi V, Petelin A, Jenuš T, Vidic S, Drevenšek G, Jenko Pražnikar Z. Increased Risk_Taking Behaviour and Brain_Derived Neurotrophic Factor Val66Met Polymorphism Correlates to Decreased Serum Brain_Derived Neurotrophic Factor Level in Heroin Users. *Eur Addict Res.* 2018;24(4):189_200. doi: 10.1159/000492582.

de Hoogt R, Estrada MF, Vidic S, Davies EJ, Osswald A, Barbier M, Santo VE, Gjerde K, van Zoggel HJAA, Blom S, Dong M, Närhi K, Boghaert E, Brito C, Chong Y, Sommergruber W, van der Kuip H, van Weerden WM, Verschuren EW, Hickman J, Graeser R. Protocols and characterization data for 2D, 3D, and slice_based tumor models from the PREDECT project. *Sci Data.* 2017 Nov 21;4:170170. doi: 10.1038/sdata.2017.170.

Stock K, Estrada MF, Vidic S, Gjerde K, Rudisch A, Santo VE, Barbier M, Blom S, Arundkar SC, Selvam I, Osswald A, Stein Y, Gruenewald S, Brito C, van Weerden W, Rotter V, Boghaert E, Oren M, Sommergruber W, Chong Y, de Hoogt R, Graeser R. Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery. *Sci Rep.* 2016 Jul 1;6:28951. doi: 10.1038/srep28951.

Barbier M, Jaensch S, Cornelissen F, Vidic S, Gjerde K, de Hoogt R, Graeser R, Gustin E, Chong YT; IMI PREDECT Consortium. Ellipsoid Segmentation Model for Analyzing Light_Attenuated 3D Confocal Image Stacks of Fluorescent Multi_Cellular Spheroids. *PLoS One.* 2016 Jun 15;11(6):e0156942. doi: 10.1371/journal.pone.0156942.

Hickman JA, Graeser R, de Hoogt R, Vidic S, Brito C, Gutekunst M, van der Kuip H; IMI PREDECT Consortium. Three_dimensional models of cancer for pharmacology and cancer cell biology: capturing tumor complexity in vitro/ex vivo. *Biotechnol J.* 2014 Sep;9(9):1115_28. doi:10.1002/biot.201300492. Review.

Cemazar M, Golzio M, Sersa G, Escoffre JM, Coer A, Vidic S, Teissie J. Hyaluronidase and collagenase increase the transfection efficiency of gene electrotransfer in various murine tumors. *Hum Gene Ther.* 2012 Jan;23(1):128_37. doi: 10.1089/hum.2011.073.

Kamensek U, Sersa G, Vidic S, Tevz G, Kranjc S, Cemazar M. Irradiation, cisplatin, and 5_azacytidine upregulate cytomegalovirus promoter in tumors and muscles: implementation of non_invasive fluorescence imaging. *Mol Imaging Biol.* 2011 Feb;13(1):43_52. doi: 10.1007/s11307_010_0300_6.

Vidic S, Markelc B, Sersa G, Coer A, Kamensek U, Tevz G, Kranjc S, Cemazar M. MicroRNAs targeting mutant K_ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo. *Cancer Gene Ther.* 2010 Jun;17(6):409_19. doi: 10.1038/cgt.2009.87.

Kranjc S, Tevz G, Kamensek U, Vidic S, Cemazar M, Sersa G. Radiosensitizing effect of electrochemotherapy in a fractionated radiation regimen in radiosensitive murine sarcoma and radioresistant adenocarcinoma tumor model. *Radiat Res.* 2009 Dec;172(6):677_85. doi: 10.1667/RR1873.1.

Tevz G, Kranjc S, Cemazar M, Kamensek U, Coer A, Krzan M, Vidic S, Pavlin D, Sersa G. Controlled systemic release of interleukin_12 after gene electrotransfer to muscle for cancer gene therapy alone or in combination with ionizing radiation in murine sarcomas. *J Gene Med.* 2009 Dec;11(12):1125_37. doi: 10.1002/jgm.1403.

Cemazar M, Golzio M, Sersa G, Hojman P, Kranjc S, Vidic S, Rols MP, Teissie J. Control by pulse parameters of DNA electrotransfer into solid tumors in mice. *Gene Ther.* 2009 May;16(5):635_44. doi: 10.1038/gt.2009.10.

Tevz G, Pavlin D, Kamensek U, Kranjc S, Vidic S, Coer A, Sersa G, Cemazar M. Gene electrotransfer into murine skeletal muscle: a systematic analysis of parameters for long_term gene expression. *Technol Cancer Res Treat.* 2008 Apr;7(2):91_101.

Vidic S, Pavlin D, Sersa G, Coer A, Kranjc S, Grosel A, Tevz G, Cemazar M. The effect of the histological properties of tumors on transfection efficiency of electrically assisted gene delivery to solid tumors in mice. *Gene Ther.* 2007 Sep;14(17):1261_9.

Cemazar M, Pavlin D, Kranjc S, Grosel A, Vidic S, Sersa G. Sequence and time dependence of transfection efficiency of electrically_assisted gene delivery to tumors in mice. *Curr Drug Deliv.* 2006 Jan;3(1):77_81. Vidic S, Legisa M. Posttranslational modification of 6_phosphofructo_1_kinase in *Aspergillus niger*. *Appl Environ Microbiol.* 2005 Mar;71(3):1425_32.

Projects

2012-2014: PREDECT (Innovative Medicines Initiative): [New models for preclinical evaluation of drug efficacy in common solid tumours](#)

Memberships

EMA 2021 - present: Member of the Committee for Advanced Therapies (CAT), EMA (representative of Slovenia)

EMA: 2019 - 2025: Member of the CHMP Biologics Working Party (BWP),

HMA 2020 - 2025: Member of the HMA Biosimilar working group (BSWG)

Other Relevant Information